1. 1 Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci. 2003;24:619–625.
2. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
3. 3 The ICH Steering Committee. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs (E14). The international conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH). The Guideline was recommended for adoption at Step 4 of the ICH process in May 2005 (http://www.ich.org/).
4. 4 The ICH Steering Committee. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B). The international conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH). The Guideline was recommended for adoption at Step 4 of the ICH process in May 2005 (http://www.ich.org/).
5. 5 Bazett HC. An analysis of the time relations of electrogram. Heart. 1920;7:353–370.